BRICKELL BIOTECH INC (BBI)

US10802T2042 - Common Stock

2.35  +0.05 (+2.17%)

Fundamental Rating

3

Taking everything into account, BBI scores 3 out of 10 in our fundamental rating. BBI was compared to 588 industry peers in the Biotechnology industry. While BBI seems to be doing ok healthwise, there are quite some concerns on its profitability. BBI is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

BBI had negative earnings in the past year.
In the past 5 years BBI always reported negative net income.
In the past 5 years BBI always reported negative operating cash flow.

1.2 Ratios

Industry RankSector Rank
ROA -191.83%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Operating Margin and Gross Margin are not available for BBI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) -8325.47%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

BBI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BBI has been reduced compared to 1 year ago.
BBI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

BBI has an Altman-Z score of -15.04. This is a bad value and indicates that BBI is not financially healthy and even has some risk of bankruptcy.
BBI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.04
ROIC/WACCN/A
WACC9.67%

2.3 Liquidity

BBI has a Current Ratio of 4.36. This indicates that BBI is financially healthy and has no problem in meeting its short term obligations.
BBI has a Quick Ratio of 4.36. This indicates that BBI is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.36
Quick Ratio 4.36

More info and screens

4

3. Growth

3.1 Past

BBI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1880.96%.
BBI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -40.13%.
The Revenue for BBI have been decreasing by -51.15% on average. This is quite bad
EPS 1Y (TTM)-1880.96%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q46.67%
Revenue 1Y (TTM)-40.12%
Revenue growth 3Y-37.06%
Revenue growth 5Y-51.15%
Revenue growth Q2Q360%

3.2 Future

The Earnings Per Share is expected to grow by 11.32% on average over the next years. This is quite good.
The Revenue is expected to grow by 67.18% on average over the next years. This is a very strong growth
EPS Next Y70.65%
EPS Next 2Y30.88%
EPS Next 3Y19.65%
EPS Next 5Y11.32%
Revenue Next Year1253.05%
Revenue Next 2Y295.6%
Revenue Next 3Y136.3%
Revenue Next 5Y67.18%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BBI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BBI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.27

4.3 Compensation for Growth

A more expensive valuation may be justified as BBI's earnings are expected to grow with 19.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.88%
EPS Next 3Y19.65%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BBI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRICKELL BIOTECH INC

NASDAQ:BBI (9/7/2022, 7:17:32 PM)

2.35

+0.05 (+2.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap6.23M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -191.83%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) -8325.47%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.36
Quick Ratio 4.36
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-1880.96%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y70.65%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-40.12%
Revenue growth 3Y-37.06%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y